Suraksha Diagnostic Peer Comparison

NSE: SURAKSHA | BSE: 544293

₹325.45

₹9.10 (2.88%)

As on 02-Nov-2026IST

Market cap

₹1,701 Cr

Revenue (TTM)

₹325 Cr

P/E Ratio

47.5

P/B Ratio

6.6

Div. Yield

0.2 %

Edit

	Suraksha Diagnostic	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Market cap (₹ Cr)	1,701	35,199	31,722	30,108	15,038
Revenue (₹ Cr)	325	4,683	2,891	4,213	857
Net Profit (₹ Cr)	35.07	552.34	546.30	190.80	187.49
Net Margin (%)	10.67	11.55	18.23	4.49	21.32
RoE (%)	15.06	14.93	23.03	9.45	20.58
Price to Earnings	47.52	63.29	58.54	147.37	80.21
Price-To-Book	6.63	8.56	12.14	7.96	14.93

Income Statement (₹ Cr)

	Suraksha Diagnostic	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Operating Revenue	325.47	4,683.37	2,890.80	4,212.50	857.13
Total Income	328.82	4,783.78	2,995.90	4,248.00	879.41
Total Expenditure	223.39	3,704.62	2,053.10	3,379.70	495.19
EBITDA	102.09	978.75	837.70	832.80	361.94
Depreciation	43.25	246.41	171.60	330.60	96.06
EBIT	58.84	732.34	666.10	502.20	265.89
Interest	13.57	92.01	24.40	253.30	36.75
Other Income	3.35	100.41	105.10	35.50	22.28
Exceptional Items	0.00	-20.61	-30.10	-11.20	0.00
Profit before Tax	48.61	720.14	716.70	273.20	251.42
Provision for Tax	13.54	167.80	170.40	82.40	63.93
Profit after Tax	35.07	552.34	546.30	190.80	187.49

	Suraksha Diagnostic	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Shareholder's Funds	244.85	3,961.57	2,508.20	2,247.40	957.15
Minority Interest	0.73	3.84	-4.40	9.90	0.00
Non-Current Liabilities	144.99	1,293.60	154.00	3,961.30	426.03
Current Liabilities	59.65	627.13	450.70	1,238.90	123.87
Total Liabilities	448.12	5,905.00	3,139.97	7,690.70	1,507.05

	Suraksha Diagnostic	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Non-Current Assets	235.52	3,128.95	1,176.30	5,416.90	737.24
Current Assets	62.58	1,674.92	1,566.60	937.40	321.90
Total Assets	448.12	5,905.00	3,139.97	7,690.70	1,507.05
Total Debt*	1.73	631.08	0.00	3,244.00	0.00
Net Current Assets	2.93	1,047.79	1,115.90	-301.50	198.03
Contingent Liabilities	--	100.01	16.76	81.10	0.13

	Suraksha Diagnostic	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Cash From Operating Activities	81.83	714.39	635.61	510.80	270.59
Cash Flow from Investing Activities	-52.17	-1,089.11	-421.86	-1,451.70	-174.22
Cash from Financing Activities	-28.69	271.85	-263.57	940.30	-69.49
Net Cash Inflow / Outflow	0.97	-102.87	-49.83	-0.60	26.88

	Suraksha Diagnostic	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
ROCE (%)	24.97	19.38	29.56	11.51	30.28
ROE (%)	15.06	14.93	23.03	9.45	20.58
ROA (%)	8.97	10.35	18.64	2.83	13.49
EBIT Margin (%)	18.08	15.64	23.04	11.92	31.02
Net Margin (%)	10.67	11.55	18.23	4.49	21.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Suraksha Diagnostic	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Revenue Growth (%)	23.31	21.27	14.29	30.90	20.18
EBIT Growth (%)	21.06	0.94	15.64	-16.88	26.22
Net Profit Growth (%)	7.95	3.43	5.38	-52.81	24.27
EPS Growth (%)	1.03	2.70	-30.51	-42.60	23.44
Book Value Growth (%)	15.52	16.51	15.41	5.13	21.86

	Suraksha Diagnostic	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Price / Earnings	46.18	59.58	44.71	132.84	79.37
Price / Book Value	6.44	8.30	12.25	7.79	14.80
Dividend Yield (%)	0.16	0.04	1.08	0.00	0.14
EV/EBITDA	15.95	34.35	36.61	39.19	40.41
Market Cap (₹ Cr)	1,187.71	25,841.07	22,015.15	24,901.98	8,864.05

	Suraksha Diagnostic	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Debt to Equity	0.00	0.15	0.00	1.19	0.00
Short term debt to equity ratio	--	--	--	0.15	--
Current Ratio	1.05	2.67	3.48	0.76	2.60
Quick Ratio	0.91	2.54	3.38	0.68	2.56
Interest Coverage	4.58	8.83	30.37	2.08	7.84

	Suraksha Diagnostic	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Debtors to sales (%)	6.99	8.78	3.83	13.16	2.43
Asset Turnover	0.83	0.88	0.99	0.62	0.62
Receivable days	21.50	29.09	13.13	44.38	7.98
Inventory Days	9.52	6.05	5.28	7.52	2.20
Payable days	172.64	80.04	118.67	133.54	136.27
Cash Conversion Cycle	-141.62	-44.90	-100.26	-81.64	-126.08

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.